ProSci Incorporated 於1998年成立于世界生物城之一的美國加州圣地亞哥市，是世界最早和的細胞凋亡抗體生產(chǎn)廠家和供應商，公司現(xiàn)擁有17000多種單、多克隆抗體，產(chǎn)品涵蓋了細胞凋亡、信號轉(zhuǎn)導、免疫、腫瘤、細胞生物、神經(jīng)生物、傳染病等領域。ProSci公司的抗體大都經(jīng)免疫親和層析純化，經(jīng)過了嚴格的驗證測試和質(zhì)量控制，具有高純度、高親和力、特異性強等特點，可用于免疫印跡（Western blot），免疫組織化學（IHC），免疫細胞化學（ICC），酶聯(lián)免疫吸附實驗（ELISA）和細胞流式分析（FACS）等方面。ProSci的抗體產(chǎn)品已應用在1281篇SCI論文中，其中2011年的有228篇，ProSci的經(jīng)銷商和客戶都對ProSci的產(chǎn)品質(zhì)量和服務十分滿意，ProSci公司在2003、2007、2010年度都被《Nature》評為免疫學試劑推薦品牌，抗體研發(fā)、生產(chǎn)和服務優(yōu)秀供應商。
Bcl-xL Antibody: Apoptosis plays a major role in normal organism development, tissue homeostasis, and removal of damaged cells. Disruption of this process has been implicated in a variety of diseases such as cancer. Bcl-xL is a member of the Bcl-2 family of proteins that are critical regulators of apoptosis. These can be divided into two classes: those that inhibit apoptosis and those that promote cell death. Bcl-xL is an anti-apoptotic mitochondrial protein related to Bcl-w and the major transcript of the bcl-x gene. Its high expression in tumors is correlated with advanced disease and poor prognosis. Bcl-xL expression level increases in response to several stimuli such as ionizing radiation and treatment with chemotherapeutic agents.